Author:
Di Desidero Teresa,Derosa Lisa,Galli Luca,Orlandi Paola,Fontana Andrea,Fioravanti Anna,Marconcini Riccardo,Giorgi Mario,Campi Beatrice,Saba Alessandro,Lucchesi Sara,Felipetto Renato,Danesi Romano,Francia Giulio,Allegrini Giacomo,Falcone Alfredo,Bocci Guido
Funder
Associazione Italiana per la Ricerca sul Cancro
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Pharmacology,Oncology
Reference54 articles.
1. Bocci G, Kerbel R (2016) Pharmacokinetics of metronomic chemotherapy: a neglected but crucial aspect. Nat Rev Clin Oncol. doi: 10.1038/nrclinonc.2016.1064
2. Derosa L, Galli L, Orlandi P, Fioravanti A, Di Desidero T, Fontana A, Antonuzzo A, Biasco E, Farnesi A, Marconcini R, Francia G, Danesi R, Falcone A, Bocci G (2014) Docetaxel plus oral metronomic cyclophosphamide: a phase II study with pharmacodynamic and pharmacogenetic analyses in castration-resistant prostate cancer patients. Cancer 120(24):3923–3931. doi: 10.1002/cncr.28953
3. Fontana A, Falcone A, Derosa L, Di Desidero T, Danesi R, Bocci G (2010) Metronomic chemotherapy for metastatic prostate cancer: a ‘young’ concept for old patients? Drugs Aging 27(9):689–696. doi: 10.2165/11537480-000000000-00000
4. Delos Santos K, Sivanathan L, Lien K, Emmenegger U (2014) Clinical Trials of Low-Dose Metronomic Chemotherapy in Castration-Resistant Prostate Cancer In: Bocci G, Francia G (eds) Metronomic Chemotherapy: Pharmacology and Clinical Applications. Springer-Verlag, Berlin Heidelberg, pp. 119–133
5. Lord R, Nair S, Schache A, Spicer J, Somaihah N, Khoo V, Pandha H (2007) Low dose metronomic oral cyclophosphamide for hormone resistant prostate cancer: a phase II study. J Urol 177 (6):2136–2140; discussion 2140. doi: 10.1016/j.juro.2007.01.143
Cited by
25 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献